UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bisphosphonates and other bone agents for breast cancer

Cochrane database of systematic reviews, 2017-10, Vol.10 (11), p.CD003474

2017

Volltextzugriff (PDF)

Post-operative radiotherapy for ductal carcinoma in situ of the breast

Cochrane database of systematic reviews, 2013-11 (11), p.CD000563

2013

Volltextzugriff (PDF)

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy

European journal of cancer (1990), 2018-03, Vol.92, p.48-53

2018

Volltextzugriff (PDF)

Platinum chemotherapy for early triple-negative breast cancer

Breast (Edinburgh), 2024-06, Vol.75, p.103712-103712, Article 103712

2024

Volltextzugriff (PDF)

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome

Journal of translational medicine, 2023-04, Vol.21 (1), p.282-282, Article 282

2023

Volltextzugriff (PDF)

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Cancer Research and Treatment, 2021, 53(4), , pp.1084-1095

2021

Volltextzugriff (PDF)

Fulvestrant for hormone-sensitive metastatic breast cancer

Cochrane database of systematic reviews, 2017-01, Vol.1 (1), p.CD011093

2017

Volltextzugriff (PDF)

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer

Cochrane database of systematic reviews, 2020-03, Vol.3 (3), p.CD013538

2020

Volltextzugriff (PDF)

Is it time to abandon clinical breast examination?

Medical journal of Australia, 2021-11, Vol.215 (10), p.458-459

2021

Volltextzugriff (PDF)

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing

Pathology, 2024-06, Vol.56 (4), p.468-472

2024

Volltextzugriff (PDF)

Platinum-based chemotherapy for early triple-negative breast cancer

Cochrane database of systematic reviews, 2023-09, Vol.2023 (9), p.CD014805-CD014805

2023

Volltextzugriff (PDF)

High dose, high risk? What updated evidence tells us about chemotherapy dosing in early breast cancer

Cochrane database of systematic reviews, 2016-05, Vol.2016 (5), p.ED000113-ED000113

2016

Volltextzugriff (PDF)

Mainstream consent programs for genetic counseling in cancer patients: A systematic review

Asia-Pacific journal of clinical oncology, 2021-06, Vol.17 (3), p.163-177

2021

Volltextzugriff (PDF)

Risk-reducing medications for primary breast cancer: a network meta-analysis

Cochrane database of systematic reviews, 2019-04, Vol.4 (4), p.CD012191-CD012191

2019

Volltextzugriff (PDF)

An Australian mainstream genetic testing program: Clinicians views about current and future practices

Asia-Pacific journal of clinical oncology, 2024-02, Vol.20 (1), p.119-127

2024

Volltextzugriff (PDF)

Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings

The American journal of surgical pathology, 2016-05, Vol.40 (5), p.599-607

2016

Volltextzugriff (PDF)

Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer

Asia-Pacific journal of clinical oncology, 2022-10, Vol.18 (5), p.e414-e419

2022

Volltextzugriff (PDF)

Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype

Journal of medical genetics, 2022-09, Vol.59 (9), p.912-915

2022

Volltextzugriff (PDF)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Clinical cancer research, 2022-04, Vol.28 (7), p.1383-1390

2022

Volltextzugriff (PDF)

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS623-TPS623

2023

Volltextzugriff (PDF)

CIFeR: A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.12115-12115

2020

Volltextzugriff (PDF)

Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1029-1029

2021

Volltextzugriff (PDF)

Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1090-1090

2021

Volltextzugriff (PDF)

New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer

Journal of cancer education, 2017-09, Vol.32 (3), p.476-482

2017

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(60)
Buchkapitel
(1)

Sprache

Englisch
(61)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(40)
Science & Technology
(40)
Humans
(31)
Female
(27)
Oncology
(16)
Middle Aged
(14)
General & Internal Medicine
(13)
Medicine, General & Internal
(13)
Cancer
(12)
Aged
(10)
Male
(10)
Randomized Controlled Trials As Topic
(10)
Breast Neoplasms
(9)
Genetic Testing
(9)
Medicine General & Introductory Medical Sciences
(8)
Cross-Sectional Studies
(7)
Mutation
(7)
Patients
(7)
Adult
(6)
Breast Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bisphosphonates and other bone agents for breast cancer

Post-operative radiotherapy for ductal carcinoma in situ of the breast

Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy

Platinum chemotherapy for early triple-negative breast cancer

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Lynch syndrome testing of colorectal cancer patients in a high-income country with universal healthcare: a retrospective study of current practice and gaps in seven australian hospitals

Fulvestrant for hormone-sensitive metastatic breast cancer

Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer

Is it time to abandon clinical breast examination?

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing

Platinum-based chemotherapy for early triple-negative breast cancer

High dose, high risk? What updated evidence tells us about chemotherapy dosing in early breast cancer

Mainstream consent programs for genetic counseling in cancer patients: A systematic review

Risk-reducing medications for primary breast cancer: a network meta-analysis

An Australian mainstream genetic testing program: Clinicians views about current and future practices

Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings

Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer

Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer

CIFeR: A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors

Characterization of long-term responders following treatment with talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 embraca trial

Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial

New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer

Suchergebnisse filtern